NovaBridge Biosciences (NBP) Convertible Debt (2018 - 2020)

NovaBridge Biosciences (NBP) has 3 years of Convertible Debt data on file, last reported at $9.5 million in Q3 2020.

• Quarterly Convertible Debt changed N/A year-over-year to $9.5 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $9.5 million (changed N/A YoY) and the FY2019 annual result came in at $9.8 million, up 1.05% from the prior year.
• Convertible Debt declined to $9.5 million in Q3 2020 per NBP's latest filing, from $9.8 million in the prior quarter.
• Across five years, Convertible Debt topped out at $9.8 million in Q2 2020 and bottomed at $9.5 million in Q3 2020.
• The 3-year median for Convertible Debt is $9.7 million (2018), against an average of $9.7 million.
• Peak annual rise in Convertible Debt reached 0.18% in 2019, while the deepest fall reached 0.18% in 2019.
• Tracing NBP's Convertible Debt over 3 years: stood at $9.7 million in 2018, then fell by 0.18% to $9.7 million in 2019, then retreated by 1.41% to $9.5 million in 2020.
• Per Business Quant, the three latest NBP Convertible Debt figures stand at $9.5 million (Q3 2020), $9.8 million (Q2 2020), and $9.7 million (Q4 2019).

Peer Comparison